Login to Your Account

Financings Roundup

Alder Gets $38M Series D for Pipeline as BMS Carries Lead

By Trista Morrison
Staff Writer

Friday, April 20, 2012
With partner Bristol-Myers Squibb Co. handling all costs for lead antibody ALD518 in autoimmune disease, Alder BioPharmaceuticals Inc. can apply the $38 million it just raised in Series D financing to its internal pipeline.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription